Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, ...

Bayer BAYRY announced that finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone in expanding its use to patients with non-diabetic chronic kidney disease ...

Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.

Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of ...

Breast cancer isn't just a 'pink' disease; for men with a family history or genetic predisposition, a mammogram can be a ...

Just in time for St. Patrick's Day, discover why four-leaf clovers are lucky, the folklore behind the legend, how rare they ...

But it wasn't until he started to feel an odd pain that he thought something was off, too. "I started to get a little bit of ...

Tuberculosis (TB) is the world’s leading cause of death from a single infectious agent, affecting more than 10 million people ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS ...

The tiny Amazon molly (Poecilia formosa) has always fascinated researchers because, according to the rules of evolution, it ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

Hereditary ATTR-CM can run in families. Learn who may be at risk, when genetic testing is recommended, the benefits of ...